VB - Vanguard Small-Cap ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
146.9417
+0.1717 (+0.1170%)
As of 10:38AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close146.7700
Open146.9900
Bid146.9700 x 100
Ask146.9900 x 100
Day's Range146.7200 - 147.2300
52 Week Range128.5800 - 149.5800
Volume153,319
Avg. Volume615,507
Net Assets83.74B
NAV147.92
PE Ratio (TTM)N/A
Yield1.33%
YTD Return15.74%
Beta (3y)1.05
Expense Ratio (net)0.06%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • Investopedia26 days ago

    Top 3 Small-Cap ETFs for 2017

    There's a case to be made that small-cap ETFs will outperform in the final months of 2017. Here are a few to consider.

  • 5 Small-Cap ETFs That Knock Out the Competition
    InvestorPlacelast month

    5 Small-Cap ETFs That Knock Out the Competition

    When it comes to investing, small-cap stocks beat large caps as the best ETFs to buy. After all, it’ll take a lot of a behemoth like International Business Machines Corp. (NYSE:IBM) to get the ship moving. Which is why small-cap stocks have tacked on an extra 253% in cumulative extra returns over large-cap stocks.

  • The 3 Best Vanguard ETFs to Get Your ‘Risk On’
    InvestorPlacelast month

    The 3 Best Vanguard ETFs to Get Your ‘Risk On’

    While risk-takers will eschew broader-scoped exchange-traded funds (ETFs) for the glory (and profits) of individual stocks, ETFs are a relevant component of any investing strategy. While the profit potential is greatest with a bet on a single company, the opposite is also true. Over the long run, the law of averages makes choosing the best Vanguard ETFs particularly compelling.

  • Stocks Mixed As Biotechs Dive; Buffett Stocks Near Buy Point?
    Investor's Business Daily2 months ago

    Stocks Mixed As Biotechs Dive; Buffett Stocks Near Buy Point?

    Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.

  • Dow Sells Off As Boeing, GE Weigh; Chance To Buy Small Caps?
    Investor's Business Daily2 months ago

    Dow Sells Off As Boeing, GE Weigh; Chance To Buy Small Caps?

    Key U.S. stock indexes sold off Wednesday as earnings reports continued and amid renewed talk about changes to 401(k) contribution limits.

  • PowerShares Launches Small-Cap Equity ETF
    Zacks2 months ago

    PowerShares Launches Small-Cap Equity ETF

    PowerShares rolls out small-cap U.S. equity ETF.

  • Hot Areas of Last Week and Their ETFs
    Zacks3 months ago

    Hot Areas of Last Week and Their ETFs

    Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.

  • Market Realist3 months ago

    Nuplazid Sees Increasing Physician Intent to Prescribe in 2017

    Acadia Pharmaceuticals' (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.

  • Morningstar4 months ago

    Small Caps: The Easy Game for Active Managers?

    The odds may be better for small-cap managers, but they're still long.

  • Here's Why Small Cap ETFs Are Underperforming
    Zacks4 months ago

    Here's Why Small Cap ETFs Are Underperforming

    U.S. small cap ETFs suffer on account of growing uncertainty around Trump's pro-growth policies.

  • Zacks4 months ago

    U.S. Small Business Confidence Up in July: ETFs in Focus

    U.S. small business activity improves in July; beats estimates.

  • Market Realist4 months ago

    Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017

    Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.

  • Market Realist5 months ago

    Where Abiomed Plans to Expand Impella CP’s Label

    About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.

  • Market Realist6 months ago

    These Are Align Technologies Key Demand Drivers in North America

    In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).

  • What Happened in the Stock Market Today
    Motley Fool6 months ago

    What Happened in the Stock Market Today

    Palo Alto Networks leaped, Hewlett Packard Enterprise fell, and major market averages started June on a positive note.

  • ETF Basics: How to Choose the Right Exchange-Traded Fund for You
    Motley Fool7 months ago

    ETF Basics: How to Choose the Right Exchange-Traded Fund for You

    Here's how exchange-traded funds work, why they benefit retail investors, and how to pick the right ETFs for your portfolio.

  • Market Realist7 months ago

    Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017

    On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.

  • So Far, So Good for Small-Cap Earnings
    Harvest Exchange7 months ago

    So Far, So Good for Small-Cap Earnings

    With arrival of spring comes first-quarter earnings announcements throughout the stock market. Large-cap companies generally report a little earlier, business results are better than 1Q's GDP might imply, and the news so far for both small- and ...

  • Harvest Exchange7 months ago

    Small Cap Owning Large Cap, Mass Hysteria!

    By Roger Nusbaum, AdvisorShares ETF Strategist The title of this post is a play on the bit in the movie Stripes when Bill Murray talks about dogs and cats living together. You probably heard about the niche ETF (naming names is difficult for ...

  • Market Realist8 months ago

    Behind Exelixis’s Successful Commercial Launch of Cabometyx in 2016

    Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.

  • Harvest Exchange8 months ago

    Small caps looking for a catalyst

    U.S. stocks are off to another stellar year. Look below the surface, however, and the rally has had a somewhat unusual flavor. Some of the better performing stocks are in the more defensive industries, such as utilities and health care, while small ...

  • Swedroe: Following Up On 2017’s ‘Sure Things’
    ETF.com8 months ago

    Swedroe: Following Up On 2017’s ‘Sure Things’

    At the start of each year, I put together a list of predictions gurus make for the upcoming year—sort of a consensus of “sure things.” We keep track of the sure things with a review at the end of each quarter. With March behind us, it’s time for our first review. As is our practice, we give a positive score for a forecast that came true, a negative score for one that was wrong and a zero for one that was basically a tie.

  • Benzinga8 months ago

    Year Of The Stock Picker? Think Again

    Rewind back to late 2016 and early 2017 and it is easy to find a slew of articles speculating that 2017 would be the year of stock pickers and that active managers would bounce back against passive products, ...

  • The ‘Stock Picker’s Market’ That Wasn’t
    ETF.com8 months ago

    The ‘Stock Picker’s Market’ That Wasn’t

    Todd Rosenbluth is director of ETF and mutual fund research at CFRA. While 2017 was supposedly set up as a U.S. stock pickers’ market—with a new president, a Federal Reserve poised to raise rates and expectations of higher stock dispersion creating opportunities to spot winners—it is not looking good so far. Just 31% of large-cap core mutual funds ended the first quarter beating the S&P 500 index’s total return, while 33% of small-cap core funds bested the Russell 2000 Index.